Life Sciences · Nasdaq: IDXX
IDEXX Laboratories earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 1 Feb 2027
Latest: Q3 2026
IDEXX placed over 1,900 inVue Dx analyzers in the quarter and bought AI clinical assistant CoVet, extending its diagnostics-plus-software push in veterinary practices.
IDEXX's growth this quarter was driven by volume, led by the inVue Dx analyzer, which had over 1,900 placements and brings the installed base to nearly 11,000 instruments. The premium instrument base grew 11% globally, and VetLab consumables use rose with new product launches. IDEXX Cancer Dx became a multi-cancer panel. International regions grew faster than the U.S., and imaging installations were strong, led by ImageVue DR50 Plus.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $954.3M * |
| Q1 2025 | $998.4M |
| Q2 2025 | $1.1B |
| Q3 2025 | $1.1B |
| Q4 2025 | $1.1B * |
| Q1 2026 | $1.1B |
| Q2 2026 | $1.2B |
| Q3 2026 | $1.2B |
Data
| Q1 2025 | $2.96 |
| Q2 2025 | $3.63 |
| Q3 2025 | $3.40 |
| Q1 2026 | $3.47 |
| Q2 2026 | $4.27 |
| Q3 2026 | $4.01 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 27.4% |
| Q1 2025 | 31.7% |
| Q2 2025 | 33.6% |
| Q3 2025 | 32.1% |
| Q4 2025 | 28.9% |
| Q1 2026 | 31.8% |
| Q2 2026 | 35.0% |
| Q3 2026 | 33.1% |
Data
| Q4 2024 | $232.8M |
| Q1 2025 | $207.9M |
| Q2 2025 | $151.6M |
| Q3 2025 | $371.2M |
| Q4 2025 | $326.3M |
| Q1 2026 | $234.3M |
| Q2 2026 | $322.5M |
| Q3 2026 | $420.8M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $954.3Md | $998.4M | $1.1B | $1.1B | $1.1Bd | $1.1B | $1.2B | $1.2B |
| Gross margin | 59.8% | 62.4% | 62.6% | 61.8% | 60.3% | 63.4% | 64.0% | 62.9% |
| Operating income | $261.7Md | $316.5M | $373.0M | $354.8M | $315.6Md | $362.6M | $425.6M | $402.3M |
| Operating margin | 27.4% | 31.7% | 33.6% | 32.1% | 28.9% | 31.8% | 35.0% | 33.1% |
| Net income | $216.1Md | $242.7M | $294.0M | $274.6M | $248.2Md | $278.4M | $338.4M | $317.1M |
| Diluted EPS | — | $2.96 | $3.63 | $3.40 | — | $3.47 | $4.27 | $4.01 |
| Operating cash flow | $262.0Md | $238.0M | $185.7Md | $402.3Md | $355.8Md | $266.2M | $347.2Md | $449.7Md |
| Capital expenditure | $29.3Md | $30.0M | $34.1Md | $31.1Md | $29.4Md | $32.0M | $24.6Md | $28.9Md |
| Free cash flow | $232.8M | $207.9M | $151.6M | $371.2M | $326.3M | $234.3M | $322.5M | $420.8M |
| R&D expense | $57.7Md | $59.1M | $61.9M | $63.4M | $66.8Md | $65.8M | $65.4M | $68.8M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 2 Nov 202610-Q for the period ended 30 Sep 2026SEC ↗
- 4 Aug 202610-Q for the period ended 30 Jun 2026SEC ↗
- 5 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 20 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 3 Nov 202510-Q for the period ended 30 Sep 2025SEC ↗
- 4 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 1 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 21 Feb 202510-K for the period ended 31 Dec 2024SEC ↗